Welcome to our dedicated page for Nexgel SEC filings (Ticker: NXGL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The NEXGEL, Inc. (NASDAQ: NXGL) SEC filings page brings together the company’s official regulatory documents, giving investors direct insight into its hydrogel-focused healthcare and consumer products business. As a Delaware corporation listed on NASDAQ, NEXGEL files annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and proxy statements such as its definitive proxy on Schedule 14A.
In these filings, NEXGEL details its operations in ultra-gentle, high-water-content hydrogel products, its contract manufacturing relationships with consumer healthcare companies, and its portfolio of brands including SilverSeal®, Hexagels®, Turfguard®, Kenkoderm® and Silly George®. Financial statements and accompanying notes explain revenue from contract manufacturing and branded products, gross profit, operating expenses, and net loss attributable to NEXGEL stockholders.
Current reports on Form 8-K provide timely disclosure of material events, such as quarterly financial results, the spin-off of a portion of the drug delivery program into NexGelRx, changes in executive leadership, and decisions by the board of directors regarding special meetings or capital structure proposals. Proxy materials, including the company’s definitive proxy statement for a special meeting of stockholders, describe matters submitted to shareholder vote, such as proposed amendments to the certificate of incorporation.
Through this page, users can also review filings related to equity offerings, warrants, and other securities matters referenced in NEXGEL’s disclosures. Real-time updates from the SEC’s EDGAR system ensure that new NXGL filings appear promptly, while AI-powered summaries help explain the key points of lengthy documents, including complex sections on non-GAAP financial measures, risk factors, and governance provisions.
For those analyzing NXGL, this SEC filings archive offers a structured view of how NEXGEL reports its business, finances, and corporate actions over time, directly from its official submissions to regulators.
NEXGEL director Henry Scott Robert sold 7,697 shares of the company's common stock on 09/25/2025 under a pre-established Rule 10b5-1 trading plan at a weighted average price of $2.3579 per share. The shares were originally purchased on 03/01/2024. After the sale, the reporting person beneficially owns 121,356 shares, held directly. The filer notes the sale prices ranged from $2.3500 to $2.3900 and offers to provide a breakdown of shares sold at each price if requested.
Form 144 notice for proposed sale of common stock. The filing shows 35,515 shares of common stock are proposed for sale through The Charles Schwab Corporation, with an aggregate market value of $108,451 and 8,067,580 shares outstanding. The securities were acquired as compensation on 02/15/2024 in a transaction described as "COMPENSATION / DEAL ACQUIRED BETWEEN: 2/15/24 TO 11/5/24" and payment is recorded as of 02/15/2024. The filer reports no securities sold during the past three months. The notice includes the standard representation that the seller is not aware of any undisclosed material adverse information.